Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
Creator
Smith, Emily
Excler, Jean-Louis
Gurwith, Marc
Kim, Denny
Khuri-Bulos, Najwa
Kochhar, Sonali
Wood, David
Whelan, Mike
Klug, Bettina
Robertson, James
Condit, Richard
Fast, Patricia
Chen, Robert
Drew, Stephen
Source
Elsevier; Medline; PMC
abstract
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.
has issue date
2020-07-09
(
xsd:dateTime
)
bibo:doi
10.1016/j.vaccine.2020.06.044
bibo:pmid
32653276
has license
no-cc
sha1sum (hex)
43ae2557d4376a510699cadc7d154406e975d54d
schema:url
https://doi.org/10.1016/j.vaccine.2020.06.044
resource representing a document's title
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
has PubMed Central identifier
PMC7343648
has PubMed identifier
32653276
schema:publication
Vaccine
resource representing a document's body
covid:43ae2557d4376a510699cadc7d154406e975d54d#body_text
is
schema:about
of
named entity 'key'
named entity 'immunogenic'
named entity 'viral vector'
named entity 'quality control'
named entity 'immune response'
named entity 'vaccine'
named entity 'Brighton Collaboration'
named entity 'vaccination'
named entity 'clinical testing'
named entity 'vaccine'
named entity 'Protein vaccines'
named entity 'VLPs'
named entity 'antigens'
named entity 'adjuvants'
named entity 'hepatitis'
named entity 'PubMed'
named entity 'antibody-dependent enhancement'
named entity 'Brighton Collaboration'
named entity 'recombinant'
named entity 'gmail'
named entity 'viruses'
named entity 'vaccine'
named entity 'CEPI'
named entity 'live attenuated'
named entity 'Coalition for Epidemic Preparedness Innovations'
named entity 'protein vaccines'
named entity 'vaccine safety'
named entity 'vaccine'
named entity 'adjuvant'
named entity 'adverse effects'
named entity 'recombinant'
named entity 'Ebola'
named entity 'ADE'
named entity 'protein'
named entity 'immune response'
named entity 'antigen'
named entity 'COVID-19'
named entity 'vaccine'
named entity 'COVID-19'
named entity 'toxicity'
named entity 'WHO'
named entity 'respiratory disease'
named entity 'method of administration'
named entity 'adjuvants'
named entity 'immunogenicity'
named entity 'Peptides'
named entity 'vaccine'
named entity 'Brighton Collaboration'
named entity 'viral vector'
named entity 'Ebola vaccines'
named entity 'viral vector'
named entity 'CEPI'
named entity 'peptide vaccines'
named entity 'vaccine'
named entity 'vaccine'
named entity 'VLPs'
named entity 'vaccine'
named entity 'COVID'
named entity 'spike protein'
named entity 'adverse effects'
named entity 'adjuvant'
named entity 'virus'
named entity 'influenza vaccine'
named entity 'herpes zoster vaccine'
named entity 'Vaccine'
named entity 'vaccine'
named entity 'Adjuvants'
named entity 'infection'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 2
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software